Sartorius, DE0007165631

RBC keeps EUR 220.00 target for Sartorius stock

Published on 10/06/2026 at 12:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius revenue grew 6.70 percent in constant currencies through June 2026. Sartorius stock costs EUR 265.75 on October 6, 2026 after EUR 251.95.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern
Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) was trading at EUR 265.75 at Lang & Schwarz on October 6, 2026 at 12:23 p.m. CEST, up 5.48 percent from the prior close of EUR 251.95. The latest analyst signal came from RBC, which kept its Sector Perform rating and EUR 220.00 target after updating its model on October 5, 2026, according to FinanzNachrichten.

RBC target stays below the quote

RBC's EUR 220.00 target stands EUR 45.75 below the Lang and Schwarz price, a gap of 17.22 percent based on the two euro values. The bank said its assessment reflected US tariff refunds, the MatTek acquisition and currency changes, while the effect on 2026 sales forecasts was minimal, FinanzNachrichten reported on October 6, 2026.

The view contrasts with recent target increases. Goldman Sachs lifted its target from EUR 228.00 to EUR 244.00 while keeping Neutral on September 30, 2026, according to FinanzNachrichten. Barclays raised its target from EUR 300.00 to EUR 310.00 and retained Overweight on September 30, 2026, FinanzNachrichten reported.

Revenue recovery reaches 6.70 percent

For January to June 2026, Sartorius revenue rose 6.70 percent year over year in constant currencies, according to Troy Technical. Sartorius' investor-relations page identifies the period as the Group's half-year results and describes bioprocess solutions and laboratory products as its two operating divisions, Sartorius states.

JPMorgan expects Sartorius to slightly exceed expectations in the third quarter and referred to an October 22, 2026 reporting date, while keeping a EUR 295.00 target and Overweight rating, according to FinanzNachrichten on September 28, 2026. That expectation places consumables growth and equipment stabilization at the center of the next result.

Stock sits below its yearly high

The finance quote showed a 52-week range of EUR 198.50 to EUR 270.00 as of October 6, 2026. At EUR 265.75, Sartorius stock stood EUR 4.25 below the high, or 1.57 percent below it, while the market capitalization was EUR 18.3 billion.

At Lang & Schwarz, Sartorius stock was trading at EUR 265.75 on October 6, 2026 at 12:23 p.m. CEST, plus 5.48 percent versus the prior close of EUR 251.95 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.

Sartorius stock facts

  • Company: Sartorius AG
  • ISIN: DE0007165631
  • WKN: 716563
  • Ticker: SRT3
  • Primary exchange: Xetra
  • Price Lang & Schwarz as of October 6, 2026 at 12:23 p.m. CEST: EUR 265.75
  • Change versus prior close: plus 5.48 percent
  • Prior close Lang & Schwarz October 5, 2026: EUR 251.95
  • Market capitalization: EUR 18.3 billion as of October 6, 2026
  • 52-week range: EUR 198.50-EUR 270.00 as of October 6, 2026
  • Sector / Industry: Health care / Advanced Medical Equipment and Technology
  • Index membership: MDAX and TecDAX

More news and analyses on Sartorius stock

Disclaimer...

en | DE0007165631 | SARTORIUS | boerse | 70241388 | bgmi